Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)

Thomas Melchardt, Rebecca I Wurm-Kuczera, Bettina Altmann, Petra Pichler, Manuel Orlinger, Michael Panny, Luisa Wohn, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Richard Greil, Bjoern Chapuy

Blood (2023) 142 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2023-188854

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Blood (2023) 142 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2023-185992

Published: 2023

Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Blood (2022) 140 (Supplement 1): 1346–1349.

https://doi.org/10.1182/blood-2022-168521

Published: 2022

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group

Lisa Pleyer, Sonja Heibl, Christoph Tinchon, Sonja Vallet, Branka Petricevic, Michael Leisch, Alexander Egle, Thomas Melchardt, Gudrun Piringer, Dominik Wolf, Richard Beswick, Manuel Drost, Julian Larcher-Senn, Thomas Grochtdreis, Richard Greil, Reinhard Stauder

Blood (2021) 138 (Supplement 1): 64.

https://doi.org/10.1182/blood-2021-145281

Published: 2021

Journal Articles

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Blood (2021) 138 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2021-145401

Published: 2021

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140918

Published: 2020

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Barbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, Alexander Egle, Peter Neumeister, Daniela Voskova, Marius Erik Mayerhoefer, Ingrid Simonitsch-Klupp, Thomas Melchardt, Richard Greil, Markus Raderer

Blood (2017) 129 (3): 383–385.

https://doi.org/10.1182/blood-2016-06-720599

Published: 2017

Journal Articles

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Blood (2015) 126 (23): 1603.

https://doi.org/10.1182/blood.V126.23.1603.1603

Published: 2015

Journal Articles

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Blood (2015) 126 (23): 4056.

https://doi.org/10.1182/blood.V126.23.4056.4056

Published: 2015

Journal Articles

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Heinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, Josef Thaler, Ernst Schloegl, Guenther A. Gastl, Dominik Wolf, Robert Kralovics, Bettina Gisslinger, Karin Strecker, Alexander Egle, Thomas Melchardt, Sonja Burgstaller, Ella Willenbacher, Martin Schalling, Nicole C. Them, Pavla Kadlecova, Christoph Klade, Richard Greil

Blood (2015) 126 (15): 1762–1769.

https://doi.org/10.1182/blood-2015-04-637280

Published: 2015

Includes: Supplemental data

Journal Articles

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Thomas Melchardt, MD, Clemens Hufnagl, MSC, Oliver Weigert, MD, David M. Weinstock, MD, Nadja Kopp, MA, Lukas Weiss, MD PhD, Daniel Neureiter, MD, Wolfgang Tränkenschuh, MD, Hubert Hackl, Dr, Richard Greil, MD, Alexander Egle, MD

Blood (2014) 124 (21): 77.

https://doi.org/10.1182/blood.V124.21.77.77

Published: 2014

Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Blood (2014) 124 (21): 20.

https://doi.org/10.1182/blood.V124.21.20.20

Published: 2014

Journal Articles

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, MSc, Karin Strecker, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Pavla Kadlecova, PhD, Oleh Zagrijtschuk, MD, Christoph Klade, PhD, Richard Greil, MD

Blood (2014) 124 (21): 3177.

https://doi.org/10.1182/blood.V124.21.3177.3177

Published: 2014

Journal Articles

Spliceosome Mediated RNA Trans -Splicing for Targeting Kappa + B-Cell Neoplasms

Lukas Weiss, MD PhD, Christina Gruber, PhD, Ulrich Koller, PhD, Josefina Piñón-Hofbauer, PhD, Stefan Hainzl, PhD, Clemens Hufnagl, MSC, Thomas Melchardt, MD, Gabriele Brachtl, PhD, Richard Greil, MD, Johann Bauer, MD, Alexander Egle, MD

Blood (2014) 124 (21): 3633.

https://doi.org/10.1182/blood.V124.21.3633.3633

Published: 2014

Journal Articles

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Daniel Lechner, MD, Karin Strecker, MD, Alexander Egle, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Oleh Zahriychuk, MD, MSc, Christoph Klade, PhD, Richard Greil, MD

Blood (2013) 122 (21): 4046.

https://doi.org/10.1182/blood.V122.21.4046.4046

Published: 2013

NARROW

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Spliceosome Mediated RNA Trans -Splicing for Targeting Kappa + B-Cell Neoplasms

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only